Wall Street analysts forecast that Medidata Solutions Inc (NASDAQ:MDSO) will report sales of $180.06 million for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Medidata Solutions’ earnings. The lowest sales estimate is $179.00 million and the highest is $181.02 million. Medidata Solutions posted sales of $155.91 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.5%. The firm is expected to report its next quarterly earnings results on Tuesday, July 23rd.
On average, analysts expect that Medidata Solutions will report full year sales of $740.14 million for the current year, with estimates ranging from $737.50 million to $742.40 million. For the next fiscal year, analysts forecast that the business will post sales of $852.14 million, with estimates ranging from $840.00 million to $865.65 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, April 30th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. Medidata Solutions had a net margin of 7.99% and a return on equity of 9.28%. The business had revenue of $173.50 million during the quarter, compared to the consensus estimate of $172.12 million. During the same quarter last year, the firm earned $0.40 earnings per share. Medidata Solutions’s quarterly revenue was up 16.3% on a year-over-year basis.
MDSO traded up $0.05 during midday trading on Friday, hitting $90.95. The company had a trading volume of 39,021 shares, compared to its average volume of 1,025,082. Medidata Solutions has a 52 week low of $60.10 and a 52 week high of $98.60. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.29. The stock has a market cap of $5.65 billion, a P/E ratio of 94.75, a price-to-earnings-growth ratio of 7.48 and a beta of 1.22. The stock’s 50 day simple moving average is $91.09.
In other news, Director Robert Taylor sold 3,294 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $90.88, for a total transaction of $299,358.72. Following the completion of the sale, the director now directly owns 41,757 shares of the company’s stock, valued at $3,794,876.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 4.70% of the company’s stock.
Large investors have recently bought and sold shares of the company. Quadrant Capital Group LLC increased its position in shares of Medidata Solutions by 126.8% during the first quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 331 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of Medidata Solutions by 26.9% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock worth $87,000 after acquiring an additional 273 shares in the last quarter. Canton Hathaway LLC bought a new stake in shares of Medidata Solutions during the first quarter worth about $109,000. Advisor Group Inc. increased its position in shares of Medidata Solutions by 27.1% during the fourth quarter. Advisor Group Inc. now owns 2,553 shares of the company’s stock worth $173,000 after acquiring an additional 545 shares in the last quarter. Finally, Stephens Inc. AR increased its position in shares of Medidata Solutions by 8.7% during the fourth quarter. Stephens Inc. AR now owns 2,722 shares of the company’s stock worth $184,000 after acquiring an additional 218 shares in the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Article: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.